Christian Todd Nichols Sells 5,208 Shares of Alkermes plc (NASDAQ:ALKS) Stock

Alkermes plc (NASDAQ:ALKS) SVP Christian Todd Nichols sold 5,208 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total transaction of $151,813.20. Following the transaction, the senior vice president now owns 60,703 shares in the company, valued at approximately $1,769,492.45. The trade was a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Alkermes Price Performance

Alkermes stock traded up $0.07 during mid-day trading on Wednesday, reaching $29.32. 943,192 shares of the company were exchanged, compared to its average volume of 1,825,540. The firm has a market cap of $4.74 billion, a PE ratio of 15.00, a PEG ratio of 0.98 and a beta of 0.47. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03. The company has a fifty day simple moving average of $27.95 and a 200-day simple moving average of $26.45. Alkermes plc has a 12 month low of $22.22 and a 12 month high of $32.88.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. V Square Quantitative Management LLC bought a new position in shares of Alkermes in the 3rd quarter valued at $29,000. Signaturefd LLC boosted its stake in shares of Alkermes by 51.2% in the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock valued at $34,000 after purchasing an additional 480 shares in the last quarter. Hexagon Capital Partners LLC grew its holdings in shares of Alkermes by 3,841.0% during the 2nd quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock valued at $37,000 after purchasing an additional 1,498 shares during the last quarter. GAMMA Investing LLC increased its position in Alkermes by 44.4% during the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock worth $55,000 after purchasing an additional 703 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new position in shares of Alkermes in the 2nd quarter valued at $116,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ALKS. Cantor Fitzgerald lowered their price objective on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. JPMorgan Chase & Co. lowered their price target on Alkermes from $32.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. HC Wainwright reaffirmed a “neutral” rating and issued a $37.00 price objective on shares of Alkermes in a research report on Friday, October 25th. The Goldman Sachs Group reduced their target price on Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Finally, Mizuho raised their price target on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.42.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.